Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
News|Articles|May 16, 2018
Bench-Top System Streamlines Chromatography Operations
Author(s)Pharmaceutical Technology Editors
The ÄKTA pilot 600 from GE Healthcare is a lightweight bench-top chromatography system suited to streamline both GMP and non-GMP everyday operations.
The ÄKTA pilot 600 from GE Healthcare is a lightweight bench-top chromatography system suited to streamline both GMP and non-GMP everyday operations. The instrument’s modular design allows for functionality to be added or removed as user requirements change. The flow and pressure range support both production of technical batches and scale-up studies as well as small-scale production of GMP-grade material. The interactive process picture enables changes to be made in real-time, and deviations are quickly identified. The accuracy and range of the pumps facilitates precise gradient formation that supports a column sizes range of 26 to 200 mm i.d.
The system works with the company’s AxiChrom chromatography columns through the intelligent packing function and the packing port. Prepacked 1- and 2.5-L ReadyToProcess columns can also be used with the system.The compact design allows for easy movement and placement on a lab bench or a ReadyKart mobile station, with all functional parts placed on one side of the instrument for convenient access.
Source:
Related to this article
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
5